FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

Until recently in the United States, no products were approved for second‐line treatment of advanced urothelial carcinoma. On May 18, 2016, the U.S. Food and Drug Administration approved atezolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Yang‐Min, Suzman, Daniel, Maher, V. Ellen, Zhang, Lijun, Tang, Shenghui, Ricks, Tiffany, Palmby, Todd, Fu, Wentao, Liu, Qi, Goldberg, Kirsten B., Kim, Geoffrey, Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469588/
https://www.ncbi.nlm.nih.gov/pubmed/28424325
http://dx.doi.org/10.1634/theoncologist.2017-0087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469588/
https://www.ncbi.nlm.nih.gov/pubmed/28424325
http://dx.doi.org/10.1634/theoncologist.2017-0087

Ejemplares similares